Clinical Trial

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-03-06; most recent amendment 2026-07-06.
Trial Details
NCT Number NCT05270200
Lead Sponsor Zhujiang Hospital
Conditions Leukemia, Myeloid, Acute
Enrollment 40 participants
Start Date 2022-02-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-07